Tat-modified leptin is more accessible to hypothalamus through brain-blood barrier with a significant inhibition of body-weight gain in high-fat-diet ded mice

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 1, 2010, Pages 31-37

  Zhang, C ^a,b   Su, Z ^a,b   Zhao, B ^a   Qu, Q ^a,b   Tan, Y ^b,c   Cai, L ^b,c,e   Li, X ^a,b,d  

^a JILIN AGRICULTURAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c University of Louisville School of Medicine   (United States)

^d JINAN UNIVERSITY   (China)

^e MDR 533 ^*  (United States)

Author keywords

Blood brain barrier; Body weight; Leptin; Obesity; Tat

Indexed keywords

HYBRID PROTEIN; LEPTIN; TRANSACTIVATOR PROTEIN; TAT LEPTIN; TAT PTD 9 PROTEIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; GENE SYNTHESIS; HYPOTHALAMUS; IMMUNOREACTIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL MODEL; BAGG ALBINO MOUSE; BODY WEIGHT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE FUSION; GENE INSERTION; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MOLECULAR SIZE; OBESITY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN RENATURATION; PROTEIN TRANSPORT; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD-BRAIN BARRIER; DIETARY FATS; DRUG DELIVERY SYSTEMS; GENES, TAT; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; LEPTIN; MALE; MICE; MICE, INBRED BALB C; OBESITY; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; TISSUE DISTRIBUTION; WEIGHT GAIN;

EID: 76749145109     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1202273     Document Type: Article

References (35)

1. Arch JR, Stock MJ, Trayhurn P. Leptin resistance in obese humans: does it exist and what does it mean? Int J Obes Relat Metab Disord 1998 22 1159-1163
2. Cao G, Pei W, Ge H, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002 22 5423-5431
3. Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal-fluid/ serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996 348 159-161
4. Considine RV, Considine EL, Williams CJ, et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995 95 2986-2988
5. Considine RV, Considine EL, Williams CJ, et al. The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 1996a 45 992-994
6. Considine RV, Considine EL, Williams CJ, et al. Mutation screening and identification of a sequence variation in the human ob gene coding region. Biochem Biophys Res Commun 1996b 220 735-739
7. Dietz GP, Valbuena PC, Dietz B, et al. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res 2006 1082 61-66
8. El-Hage N, Wu G, Ambati J, et al. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 2006 178 9-16
9. El-Haschimi K, Lehnert H. Leptin resistance or why leptin fails to work in obesity. Exp Clin Endocrinol Diabetes 2003 111 2-7
10. Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 2008 5 105-117
11. Gump JM, Dowdy SF. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 2007 13 443-448
12. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995 269 543-546
13. Hamilton BS, Paglia D, Kwan AY, et al. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995 1 953-956
14. Huq I, Ping YH, Tamilarasu N, et al. Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides. Biochemistry 1999 38 5172-5177
15. Jeong KJ, Lee SY. High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification. Appl Environ Microbiol 1999 65 3027-3032
16. Kim D, Jeon C, Kim JH, et al. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res 2006 312 1277-1288
17. Klein S, Coppack SW, Mohamed-Ali V, et al. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996 45 984-987
18. Lindgren M, Hallbrink M, Prochiantz A, et al. Cell-penetrating peptides. Trends Pharmacol Sci 2000 21 99-103
19. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995 1 1155-1161
20. Nagayoshi C, Ishibashi M, Kita Y, et al. Expression, refolding and characterization of human brain serine racemase in Escherichia coli with N-terminal His-tag. Protein Pept Lett 2005 12 487-490
21. Oliveros H, Villamor E. Obesity and mortality in critically ill adults: a systematic review and meta-analysis. Obesity (Silver Spring) 2008 16 515-521
22. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995 269 540-543
23. Reece EA. Obesity, diabetes, and links to congenital defects: a review of the evidence and recommendations for intervention. J Matern Fetal Neonatal Med 2008 21 173-180
24. Schwartz MW, Peskind E, Raskind M, et al. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996 2 589-593
25. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996 45 988-991
26. Sengoku T, Bondada V, Hassane D, et al. Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity. Exp Neurol 2004 188 161-170
27. Shimizu H, Oh IS, Okada S, et al. Leptin resistance and obesity. Endocr J 2007 54 17-26
28. Steinberg GR, Dyck DJ, Calles-Escandon J, et al. Chronic leptin administration decreases fatty acid uptake and fatty acid transporters in rat skeletal muscle. J Biol Chem 2002 277 8854-8860
29. Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2006 72 211-222
30. Trogdon JG, Finkelstein EA, Hylands T, et al. Indirect costs of obesity: a review of the current literature. Obes Rev 2008
31. Van Heek M, Compton DS, France CF, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997 99 385-390
32. Weigle DS, Bukowski TR, Foster DC, et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 1995 96 2065-2070
33. Woodside B, Abizaid A, Jafferali S. Effect of acute food deprivation on lactational infertility in rats is reduced by leptin administration. Am J Physiol 1998 274 R1653-1658
34. Yin W, Cao G, Johnnides MJ, et al. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 2006 21 358-371
35. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 372 425-432